{"id":34671,"date":"2026-03-18T20:16:31","date_gmt":"2026-03-18T20:16:31","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/34671\/"},"modified":"2026-03-18T20:16:31","modified_gmt":"2026-03-18T20:16:31","slug":"roche-boosts-ai-infrastructure-with-additional-nvidia-chips-stock-rises","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/34671\/","title":{"rendered":"Roche Boosts AI Infrastructure with Additional Nvidia Chips, Stock Rises"},"content":{"rendered":"

Swiss pharma giant Roche (RHHBY)<\/a> announced that it is expanding its AI (artificial intelligence<\/a>) infrastructure by deploying an AI factory powered by 2,176 Nvidia (NVDA)<\/a> GPUs (graphics processing units). Roche\u2019s U.S.-listed shares rose 2.6% in Monday\u2019s regular trading session.<\/p>\n

Claim 70% Off TipRanks Premium<\/a>Roche Enhances AI Capabilities with Nvidia GPUs<\/p>\n

Roche highlighted that with the addition of the 2,176 Nvidia chips, the company\u2019s combined on-premises and cloud infrastructure now exceeds 3,500 Blackwell GPUs, which is the \u201cgreatest announced GPU footprint available to a pharmaceutical company.\u201d<\/p>\n

The company expects its enhanced AI infrastructure to accelerate the development of diagnostics solutions and therapeutics. Roche\u2019s collaboration with Nvidia began in 2023. The company expects the latest deployment of Nvidia\u2019s Blackwell chips to boost drug development through high-quality data and AI.<\/p>\n

Furthermore, Nvidia\u2019s BioNeMo platform enhances Roche\u2019s Lab-in-the-Loop, in which biological and chemical experiments are linked to the company\u2019s AI models, enabling scientists to test hypotheses at scale and accelerate drug discovery. Similarly, NVIDIA Omniverse libraries will optimize Roche\u2019s manufacturing, while NVIDIA Parabricks software will enhance diagnostics. In digital health, Roche leverages NVIDIA NeMo Guardrails to deliver reliable healthcare-grade conversational AI.<\/p>\n

Is Roche Stock a Buy, Hold, or Sell?<\/p>\n

Despite Roche\u2019s AI focus, Wall Street is sidelined on the stock. Recently, BNP Paribas analyst Peter Verdult<\/a> downgraded Roche stock to Hold from Buy with a price target of $50. The 4-star analyst lowered his estimates for Roche following the company\u2019s recent pipeline updates, noting that major clinical updates are not coming until 2027.<\/p>\n

Overall, Wall Street has a Hold consensus rating on Roche stock based on three Holds and one Buy recommendation. The average RHHBY stock price target<\/a> of $61 indicates 18.6% upside potential. RHHBY stock has risen 19.5% over the past year.<\/p>\n

Disclaimer & Disclosure<\/a>Report an Issue<\/a><\/p>\n

\"\"<\/a>This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Swiss pharma giant Roche (RHHBY) announced that it is expanding its AI (artificial intelligence) infrastructure by deploying an…\n","protected":false},"author":2,"featured_media":34672,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[432,429,428,431,430,433,20497,11467,134,436],"class_list":["post-34671","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-futures","tag-index-market-quote","tag-index-market-quotes","tag-index-market-symbol","tag-index-market-symbols","tag-indices","tag-nvda","tag-nvidia-corp","tag-roche","tag-the-globe-and-mail"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116252022219695663","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/34671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=34671"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/34671\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/34672"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=34671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=34671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=34671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}